Neurocrine Biosciences
NBIX
368 hedge funds and large institutions have $7.91B invested in Neurocrine Biosciences in 2020 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 139 increasing their positions, 140 reducing their positions, and 63 closing their positions.
17% more call options, than puts
Call options by funds: $62.4M | Put options by funds: $53.4M
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2.29% more ownership
Funds ownership: 96.65% → 98.95% (+2.3%)
1% less repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 140
6% less funds holding
Funds holding: 391 → 368 (-23)
17% less capital invested
Capital invested by funds: $9.56B → $7.91B (-$1.66B)
32% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 63
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$72.5M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$63.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$56.1M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$49.6M |
| 5 |
JP Morgan Chase
New York
|
+$40.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$70.5M |
| 2 |
PA
Perceptive Advisors
New York
|
-$53.8M |
| 3 |
Two Sigma Investments
New York
|
-$35.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$29.9M |
| 5 |
Millennium Management
New York
|
-$26.4M |
NBIX Hedge Fund Activity: Q1 2020 in Review
368 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2020, worth a combined $7.91B — down 17% from $9.56B a quarter earlier.
Sellers outnumbered buyers: 63 funds closed out of NBIX and 43 opened new positions — a net loss of 20 holders — while 140 trimmed existing stakes and 139 added.
The largest buyer was HealthCor Management, adding an estimated $72.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $70.5M.
- 368 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2020, down from 391 in Q4 2019.
- Funds reported $7.91B of Neurocrine Biosciences stock for Q1 2020, down 17% quarter-over-quarter.
- 43 funds opened new Neurocrine Biosciences positions in Q1 2020 and 63 closed out, a net change of -20 holders.
- The largest Neurocrine Biosciences buyer in Q1 2020 was HealthCor Management, an estimated $72.5M added.
- The largest Neurocrine Biosciences seller in Q1 2020 was T. Rowe Price Associates, an estimated $70.5M sold.
Based on aggregated 13F filings for Q1 2020.